Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase 3 Trial Comparing Upfront Surgery versus Neoadjuvant modified FOLFIRINOX in Patients with Resectable Pancreatic Cancer
KCT0007327Phase 3Active, not recruiting
- Sponsor
- Boryung
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of FOLFIRINOX in pancreatic cancer (PC) (2 arms), sponsored by Boryung. Primary endpoint: overall survival. Started Nov 2022; status: active, not recruiting.
02
Drugs
FOLFIRINOX
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on KCT0007327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007327.